Prosecution Insights
Prosecution Insights
16 pending office actions • 10 clients • 16 examiners • 12 art units • 0 of 16 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (38%) |
| §112 only | 2 (12%) |
| Double-patenting only | 1 (6%) |
| No statute on record | 7 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 75.0% | +23.0% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +69.0% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 54.1% | +20.8% |
| CRAIG, KAILA ANGELIQUE | 1 | 32.8% | +26.7% |
| SIMMONS, CHRIS E | 1 | 34.6% | +19.5% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +13.9% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +23.2% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.0% |
| MOLOYE, TITILAYO | 1 | 63.4% | +47.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18739149 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | MCINTOSH III, TRAVISS C | 117d overdue |
| 18343437 | Treatment for Intraocular Pressure Related Disorders | MOLOYE, TITILAYO | 92d overdue |
| 19313605 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | RAMOS LEWIS, JOSMALEN MILAGROS | 42d overdue |
| 19081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | SIMMONS, CHRIS E | 17d overdue |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | KWON, JOHN SEUNGJAI | 3d overdue |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 7d |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | VALENROD, YEVGENY | 15d |
| 19329358 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | KATAKAM, SUDHAKAR | 19d |
| Client (Assignee) | Pending OAs |
|---|---|
| Pharmacosmos Holding A/S | 3 |
| Ohio State University | 2 |
| MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2 |
| Fennec Pharmaceuticals | 2 |
| Atea Pharmaceuticals | 2 |
| Avilar Therapeutics | 1 |
| TOPIKOS SCIENTIFIC, INC. | 1 |
| Roche | 1 |
| U.S. Government | 1 |
| Lumina Pharmaceuticals Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 4 |
| 1615 | 2 |
| 1658 | 1 |
| 1654 | 1 |
| 1621 | 1 |
| 1622 | 1 |
| 1693 | 1 |
| 1699 | 1 |
| 1632 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19329358 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation | KATAKAM, SUDHAKAR | 1658 | Other | Non-Final OA | 19d | Pending | Sep 15, 2025 |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | DABKOWSKI, ERINNE R | 1654 | DP | Non-Final OA | 83d | Pending | Sep 15, 2025 |
| 19313605 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | Mayo Foundation for Medical Education and Research | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | Other | Non-Final OA | 42d overdue | Pending | Aug 28, 2025 |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | 1615 | §103 | Final Rejection | 33d | Pending | Jul 21, 2025 |
| 19081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Avilar Therapeutics, Inc. | SIMMONS, CHRIS E | 1622 | §112 | Non-Final OA | 17d overdue | Pending | Mar 17, 2025 |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | Topikos Scientific, Inc. | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 15d | Pending | Nov 04, 2024 |
| 18739149 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. | MCINTOSH III, TRAVISS C | 1693 | Other | Final Rejection | 117d overdue | Pending | Jun 10, 2024 |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 3d overdue | Pending | Sep 29, 2023 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | Pharmacosmos Holding A/S | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
| 18343437 | Treatment for Intraocular Pressure Related Disorders | Mayo Foundation for Medical Education and Research | MOLOYE, TITILAYO | 1632 | §103 | Non-Final OA | 92d overdue | Pending | Jun 28, 2023 |
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Hoffmann-La Roche, Inc. | LEE, CHIHYI NMN | 1628 | §103 | Non-Final OA | 32d overdue | Pending | Jun 16, 2023 |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | The United States Department of Veterans Affairs | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 78d overdue | Pending | May 09, 2023 |
| 17971318 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 84d overdue | Pending | Oct 21, 2022 |
| 17890130 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | Pharmacosmos Holding A/S | CORNET, JEAN P | 1628 | Other | Non-Final OA | 77d overdue | Pending | Aug 17, 2022 |
| 17718052 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | Pharmacosmos Holding A/S | BELL, SARA ELIZABETH | 1625 | Other | Non-Final OA | 36d overdue | Pending | Apr 11, 2022 |
| 17767956 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | Lumina Pharmaceuticals Inc. | JONES, DAMERON LEVEST | 1618 | §103 | Final Rejection | 9d | Pending | Apr 11, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial